This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic neuropathic pain market through 2031.
Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.
Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs
Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.
Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs
Key Highlights
- Forecasts includes the 7MM
- Forecasts covers from 2021-2031
- In the 7MM, the diagnosed prevalent cases of DNP will increase from 4,447,050 cases in 2021 to 5,157,455 cases in 2031, at an AGR of 1.60%.
- The current DNP treatment landscape includes many established analgesics that provide symptomatic relief. The main drug classes that are used l include tricyclic antidepressants (TCAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), alpha-2-delta ligands (gabapentinoids), sodium channel blockers, and topical treatments.
- The DNP market will exhibit moderate growth between 2021 and 2031, driven by the entry of four pipeline agents.
- Engensis will be welcomed by patients as the underlying pathophysiology of DNP will be targeted, rather than symptomatic treatment.
Scope
- Overview of diabetic neuropathic pain, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for diabetic neuropathic pain treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathic pain therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global diabetic neuropathic pain therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
Table of Contents
1 Diabetic Neuropathic Pain: Executive Summary1.1 DNP market will grow to $3.0 billion
1.2 Key players will struggle to maintain their competitive position
1.3 While outlook in DNP improves, opportunities remain to improve patient outcomes
1.4 Novel late-stage pipeline drugs will be a key driver of growth
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or staging systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
4.4.1 Sources used
4.4.2 Forecast assumptions and methods
4.4.3 Total prevalent cases of DNP
4.4.4 Diagnosed prevalent cases of DNP
4.4.5 Diagnosed prevalent cases of DNP by DSPN and non-DSPN
4.4.6 p-DPN among diagnosed prevalent cases of T1D and T2D
4.5 Epidemiological forecast for total prevalent cases of DNP (2021-31)
4.5.1 Total prevalent cases of DNP
4.5.2 Age-specific total prevalent cases of DNP
4.5.3 Sex-specific total prevalent cases of DNP
4.5.4 Diagnosed prevalent cases of DNP
4.5.5 Diagnosed prevalent cases of DNP by DSPN and Non-DSPN
4.5.6 p-DPN among diagnosed prevalent cases of T1D and T2D
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis overview
5.2 Treatment overview
5.3 Other KOL insights on disease management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Development of therapies with an improved efficacy profile
7.3 Development of therapies with improved safety and tolerability profile
7.4 Development of a curative or disease-modifying agent
7.5 Improving physician and public recognition of DNP
8 R&D Strategies
8.1 Overview
8.1.1 Development of analgesics with novel MOAs
8.1.2 Patient stratification
8.2 Clinical trials design
8.2.1 Clinical endpoints
8.2.2 High failure rate in DNP clinical trials
8.2.3 Patient recruitment
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologist
13.6.5 Vice President of Disease Analysis and Intelligence
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
- Contact the Publisher
Table 1: DNP: key metrics in the 7MM
Table 2: Classification of diabetic neuropathies
Table 3: Risk factors and comorbid conditions associated with DNP
Table 4: Treatment Guidelines for DNP
Table 5: DNP market - global drivers and barriers, 2021-2031
Table 6: Key events impacting sales for DNP in the US, 2021-2031
Table 7: DNP market - drivers and barriers in the US, 2021-2031
Table 8: Key events impacting sales for DNP in the 5EU, 2021-2031
Table 9: DNP market - drivers and barriers in the 5EU, 2021-2031
Table 10: Key events impacting sales for DNP in Japan, 2021-2031
Table 11: DNP market - drivers and barriers in Japan, 2021-2031
Table 12: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for DNP in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in DNP during the forecast period
Figure 3: Competitive assessment of the pipeline drugs benchmarked against the SOC, Lyrica (pregabalin)
Figure 4: Pain pathway - somatosensory system
Figure 5: The pathogenesis of diabetic neuropathy is multifactorial
Figure 6: 7MM, total prevalence of DNP (%), men and women, ages =20 years, 2021
Figure 7: 7MM, diagnosed prevalence of DNP (%), men and women, ages =20 years, 2021
Figure 8: Case flow map
Figure 9: 7MM, sources used to forecast the total prevalent cases of DNP
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of DNP
Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of DNP by DSPN and non-DSPN
Figure 12: 7MM, sources used to forecast p-DPN by T1D and T2D
Figure 13: 7MM, total prevalent cases of DNP, N, men and women, ages =20 years, 2021
Figure 14: 7MM, total prevalent cases of DNP by age, N, men and women, 2021
Figure 15: 7MM, total prevalent cases of DNP by sex, N, ages =20 years, 2021
Figure 16: 7MM, diagnosed prevalent cases of DNP, N, men and women, ages =20 years, 2021
Figure 17: 7MM, diagnosed prevalent cases of DNP by DSPN and non-DSPN, N, men and women, ages =20 years, 2021
Figure 18: 7MM, p-DPN among diagnosed prevalent cases of T1D and T2D, N, men and women, ages =20 years, 2021
Figure 19: General treatment algorithm for DNP
Figure 20: Unmet needs and opportunities in DNP
Figure 21: Overview of the development pipeline in DNP
Figure 22: Key late-stage trials for the promising pipeline agents that the publisher expects be licensed for DNP in the 7MM during the forecast period
Figure 23: Competitive assessment of the pipeline drugs benchmarked against the SOC, Lyrica (pregabalin)
Figure 24: Analysis of the company portfolio gap in DNP during the forecast period
Figure 25: Global (7MM) sales forecast by country for DNP in 2021 and 2031
Figure 26: Sales forecast by class for DNP in the 7MM in 2021 and 2031
Figure 27: Sales forecast by class for DNP in the US in 2021 and 2031
Figure 28: Sales forecast by class for DNP in the 5EU in 2021 and 2031
Figure 29: Sales forecast by class for DNP in Japan in 2021 and 2031
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- Boehringer Ingelheim
- Daiichi Sankyo Co
- Eli Lilly
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Grunenthal
- Helixmith Co
- Lexicon Pharmaceuticals
- Mitsubishi Tanabe Pharma Corp
- Mundipharma
- Novaremed AG
- Novartis
- Ono Pharmaceutical Co
- Pfizer
- Regenacy Pharmaceuticals
- Sun Pharmaceutical Industries
- UCB
- Viatris
